EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs

Reda R Mabrouk iD, Abdallah E Abdallah iD, Hazem A Mahdy, Samar A El-Kalyoubi iD, Omar Jamal Kamal iD, Tamer M Abdelghany, Mohamed F Zayed iD, Heba K Alshaeri iD, Moudi M Alasmari, Mohamed Ayman El-Zahabi iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Reda R Mabrouk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. Hauptthemen laut MEDLINE: Thalidomide, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science, Technology & Innovation Funding Authority, Science, Technology & Innovation Funding Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sixteen new thalidomide analogs were synthesized. The new candidates showed potent in vitro antiproliferative activities against three human cancer cell lines, namely hepatocellular carcinoma (HepG-2), prostate cancer (PC3), and breast cancer (MCF-7). It was found that compounds XII, XIIIa, XIIIb, XIIIc, XIIId, XIVa, XIVb, and XIVc showed IC50 values ranging from 2.03 to 13.39 µg/mL, exhibiting higher activities than thalidomide against all tested cancer cell lines. Compound XIIIa was the most potent candidate, with an IC50 of 2.03 ± 0.11, 2.51 ± 0.2, and 0.82 ± 0.02 µg/mL compared to 11.26 ± 0.54, 14.58 ± 0.57, and 16.87 ± 0.7 µg/mL for thalidomide against HepG-2, PC3, and MCF-7 cells, respectively. Furthermore, compound XIVc reduced the expression of NFκB P65 levels in HepG-2 cells from 278.1 pg/mL to 63.1 pg/mL compared to 110.5 pg/mL for thalidomide. Moreover, compound XIVc induced an eightfold increase in caspase-8 levels with a simultaneous decrease in TNF-α and VEGF levels in HepG-2 cells. Additionally, compound XIVc induced apoptosis and cell cycle arrest. Our results reveal that the new candidates are potential anticancer candidates, particularly XIIIa and XIVc. Consequently, they should be considered for further evaluation for the development of new anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideAntineoplastic AgentsMaleHumansStructure-Activity RelationshipQuinazolinesVascular Endothelial Growth Factor AAdjuvants, ImmunologicMCF-7 CellsImmunologic FactorsCell ProliferationDrug Screening Assays, AntitumorMolecular StructureApoptosisCell Line, TumorDose-Response Relationship, Drug

Stichwörter der Autor:innen

CRBNimmunomodulatoryquinazolinethalidomide

Substanzen

ThalidomideAntineoplastic AgentsQuinazolinesVascular Endothelial Growth Factor AAdjuvants, ImmunologicImmunologic Factors

Autor:innen und Institutionen

  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
  • Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhour 22511, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Port Said University, Port Said 42511, Egypt.
  • King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21461, Saudi Arabia.
  • Pharmacology & Toxicology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
  • Pharmacology & Toxicology Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo 11785, Egypt.

ORCID-Profile: Reda R Mabrouk, Abdallah E Abdallah, Samar A El-Kalyoubi, Omar Jamal Kamal, Mohamed F Zayed, Heba K Alshaeri, Mohamed Ayman El-Zahabi

Förderung

  • Science, Technology & Innovation Funding Authority
  • Science, Technology & Innovation Funding Authority

Zitieren

APA

Mabrouk, R. R., Abdallah, A. E., Mahdy, H. A., El-Kalyoubi, S. A., Kamal, O. J., Abdelghany, T. M., Zayed, M. F., Alshaeri, H. K., Alasmari, M. M., & El-Zahabi, M. A. (2023). Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512416

Vancouver

Mabrouk RR, Abdallah AE, Mahdy HA, El-Kalyoubi SA, Kamal OJ, Abdelghany TM, et al. Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512416

BibTeX
@article{Mabrouk2023,
  author = {Mabrouk, Reda R and Abdallah, Abdallah E and Mahdy, Hazem A and El-Kalyoubi, Samar A and Kamal, Omar Jamal and Abdelghany, Tamer M and Zayed, Mohamed F and Alshaeri, Heba K and Alasmari, Moudi M and El-Zahabi, Mohamed Ayman},
  title = {Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512416}
}
Kostenlos starten →